Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

Guggenheim’s Seamus Fernandez cut his rating on Novo Nordisk stock to Hold from Buy on Thursday, as did Evan David Seigerman ...

The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the ...

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported positive oral ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

A clinical practice guideline that stresses a multidisciplinary approach is intended to help clinicians manage obesity in ...

Pfizer said it will stop development of an oral weight-loss pill after a participant taking the drug in a clinical trial ...

Lilly’s aggressive pricing strategy and the launch of Zepbound, a new obesity treatment, could erode Novo's market share in the years to come. Novo Nordisk’s dominance in the diabetes care ...